Ipsen advances liver disease treatment

Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen. On the podcast this week, she discusses a breakthrough treatment for primary biliary cholerangitis and cholestatic liver disease.00:56-00:49: Background information 01:44-03:21: What are primary biliary cholerangitis (PBC) and cholestatic liver disease? 03:21-03:50: How rare is PBC? 03:50-04:45: How easy is PBC diagnosis? 04:45-05:45: What are the current treatments for the condition? 05:45-07:22: What are the challenges to innovation? 07:22-08:27: What is elafibranor? 08:27-08:37: How is it administered? 08:37-09:18: Is elafibranor taken for life? 09:18-11:08: What is the ELATIVE trial, and what were the results you presented at the AASLD Liver Meeting? 11:08-13:09: What was the reaction at the meeting? 13:09-13:55: A patient-centric approach 13:55-14:44: Is a cure for PBC a possibility? 14:44-17:20: How important are acquisitions to Ipsen’s pipeline? 17:20-18:33: Working on multiple diseases 18:33-19:58: How much impact can you have on liver diseases? 19:58-21:04: What are the next steps for elafibranor? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter